Los Angeles Capital Management LLC Affimed N.V. Transaction History

Los Angeles Capital Management LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 05, 2022	SELL	$2.27 - $4.86 $177,604 - $380,246	-78,240 Closed	0 $0
Q1 2022 May 06, 2022	SELL	$3.69 - $5.65 $319,395 - $489,047	-86,557 Reduced 52.52%	78,240 $342,000
Q4 2021 Feb 03, 2022	SELL	$5.37 - $7.07 $73,611 - $96,915	-13,708 Reduced 7.68%	164,797 $910,000
Q3 2021 Nov 08, 2021	SELL	$5.54 - $7.51 $70,967 - $96,203	-12,810 Reduced 6.7%	178,505 $1.1 Million
Q2 2021 Aug 05, 2021	SELL	$7.78 - $11.4 $411,562 - $603,060	-52,900 Reduced 21.66%	191,315 $1.63 Million
Q1 2021 May 05, 2021	SELL	$5.12 - $8.48 $787,020 - $1.3 Million	-153,715 Reduced 38.63%	244,215 $1.93 Million
Q4 2020 Feb 04, 2021	BUY	$3.16 - $7.03 $252 - $562	80 Added 0.02%	397,930 $2.32 Million
Q3 2020 Nov 02, 2020	BUY	$3.26 - $4.73 $63,830 - $92,613	19,580 Added 5.18%	397,850 $1.35 Million
Q2 2020 Aug 05, 2020	BUY	$1.58 - $4.63 $193,896 - $568,188	122,719 Added 48.02%	378,270 $1.75 Million
Q1 2020 May 04, 2020	BUY	$1.44 - $3.02 $367,993 - $771,764	255,551 New	255,551 $404,000

1.09M

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $185M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

Get notified when there are updates to the investment portfolio of Los Angeles Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Los Angeles Capital Management LLC with notifications on news.